Last reviewed · How we verify
losartan + hydrochlorothiazide, if necessary
Losartan is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, to relax blood vessels and lower blood pressure. Hydrochlorothiazide is a thiazide diuretic that increases urine production to reduce blood pressure.
Losartan is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, to relax blood vessels and lower blood pressure. Hydrochlorothiazide is a thiazide diuretic that increases urine production to reduce blood pressure. Used for Hypertension, Chronic kidney disease.
At a glance
| Generic name | losartan + hydrochlorothiazide, if necessary |
|---|---|
| Sponsor | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company |
| Drug class | Angiotensin II receptor antagonist and thiazide diuretic |
| Target | Angiotensin II receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Losartan works by blocking the angiotensin II receptor, which is part of the renin-angiotensin-aldosterone system (RAAS) that regulates blood pressure. By blocking this receptor, losartan prevents the vasoconstriction and fluid retention caused by angiotensin II, leading to a decrease in blood pressure. Hydrochlorothiazide, on the other hand, increases urine production by inhibiting the sodium-chloride cotransporter in the distal convoluted tubule, which leads to a decrease in fluid volume and a subsequent decrease in blood pressure.
Approved indications
- Hypertension
- Chronic kidney disease
Common side effects
- Dizziness
- Headache
- Fatigue
- Cough
- Diarrhea
Key clinical trials
- A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331) (PHASE3)
- Randomized Controlled Trial of Renal Denervation for Resistant Hypertension (PHASE3)
- Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |